Summary
VanEck Biotech ETF is an ETF - a fund traded on an exchange like a stock - run by VanEck. Positions inside: 27. The ten largest make up 73% of the fund.
- Yearly costs
- 0.35%
- Fund size
- $486.1M
- Positions
- 27
- Dividend yield
- 0.40%
- Running since
- 2011
What speaks for it
- Costs of 0.35% a year are below the middle of comparable funds (0.44%).
- Average yearly growth over the last ten years: 8.4%.
- It has been running since 2011.
What to watch
- The ten largest positions make up 73% of the fund, so its result rests on a few names.
- 100% of the fund is in one sector (Healthcare).
- 90% of the fund is in one country (United States).
- In the last five years its price once dropped by 40% from its high.
A fund has no Bulios Score and no Fair Price of its own - both are computed from the results of a single company. This page shows what is inside the fund and what it costs instead.
Price
Performance
- 1 month
- +3.0%
- 3 months
- +19%
- This year
- +27%
- 1 year
- +35%
- 3 years
- +61%
- 5 years
- +23%
- 10 years
- +124%
- Avg. market cap
- $102.5B
- P/E
- 28.0x
- Forward P/E
- 21.3x
- P/S
- 6.3x
- P/B
- 6.3x
- P/FCF
- 22.3x
- EV/EBITDA
- 22.6x
- Dividend yield
- 0.72%
- ROIC
- 0.4%
- ROE
- 12.8%
- Gross margin
- 67.0%
- Operating margin
- 0.9%
- Net margin
- -2.1%
- Payout ratio
- 20.1%
- Net debt/EBITDA
- 7.5x
- Beta
- 0.61
Weighted average of the 25 largest companies, which make up 100% of the fund. Banks and insurers are left out of the gross margin, the ROIC and the EBITDA figures.
What is inside?
Concentrated- 1 AMAmgen AMGN 16%
- 2 GIGilead Sciences GILD 14%
- 3 VRVertex Pharmaceuticals VRTX 7.9%
- 4 MRModerna MRNA 7.4%
- 5 RERegeneron Pharmaceuticals REGN 6.8%
- 6 NTNatera NTRA 4.8%
- 7 IQIQVIA IQV 4.5%
- 8 ARArgenx ARGX 4.0%
- 9 ILIllumina ILMN 3.9%
- 10 RVRevolution Medicines RVMD 3.9%
Positions in the fund: 27. The ten largest make up 73% of it.
Composition as of Oct 18, 2026.
Where is it spread?
One sector dominatesBy sector
- Healthcare 100%
By country
- United States 90%
- Netherlands 5.0%
- Switzerland 2.7%
- Germany 1.5%
- Other countries 1.2%
By company size
- Mega cap 16%
- Large cap 83%
- Mid cap 1.0%
By the company's market value: Mega cap from $200B, Large cap from $10B, Mid cap from $2B, Small cap from $300M, Micro cap below $300M.
Largest sector: Healthcare (100%). Largest country: United States (90%). Largest size group: Large cap (83%).
What does it cost me?
Cheap- A year from $10,000
- $35.00
- Over 20 years
- $1,714
From every $10,000 invested the fund takes $35.00 a year. You do not pay it separately - it is taken out of the fund's value. Over 20 years at 5% yearly growth that adds up to about $1,714.
How has it done?
Growing over the long run- A year on average, 10 years
- +8.4%
- Deepest drop
- -40%
- Yearly volatility
- 22%
Average yearly growth over the last ten years: 8.4%. Deepest drop in these years: 40% below the earlier high.
Does it pay dividends?
Yes, it pays out- Yield
- 0.40%
- Payments a year
- 1
- Last payment
- $0.96
Over the last 12 months it paid $0.96 per share, which is 0.40% of today's price. The last payment was $0.96 on Dec 22, 2025.
Is it easy to buy and sell?
Yes- Traded a day
- $2.04M
- Shares a day
- 8.5K
On an average day about $2.04M of the fund changes hands.
How expensive are the companies inside?
Rather expensive- P/E of the companies inside
- 28.0
- Average Bulios Score
- 53 out of 100
Weight by Bulios Fair Price
- Undervalued 31%
- Fairly valued 19%
- Overvalued 50%
On average the companies inside trade for 28.0 times their yearly profit. By Fair Price, 50% of the rated weight comes out as overvalued.
Counted from its largest companies (25), which make up 100% of the fund. Each company counts by its weight. We use the metrics, the Bulios Score and the Fair Price of the companies themselves.
Similar funds
Funds that hold much of the same. The overlap says how much of their weight they share with this fund.
| Fund | Domicile | Size | 1-year change | Dividends | ||
|---|---|---|---|---|---|---|
IB IBB iShares Biotechnology ETF | United States | 0.44% | $10.5B | +30% | Pays out | 65% |
SB SBIO.MI Invesco NASDAQ Biotech UCITS ETF | Ireland | 0.40% | $568.8M | +37% | Reinvests | 58% |
IB IBBQ Invesco Nasdaq Biotechnology ETF | United States | 0.19% | $79.9M | +30% | Pays out | 58% |
2B 2B70.DE iShares Nasdaq US Biotechnology UCITS ETF | Ireland | 0.35% | $906.2M | +37% | Reinvests | 58% |
20 203780.KS MiraeAsset TIGER NASDAQ BIO ETF | South Korea | 0.30% | $76.4M | +22% | Reinvests | 57% |
TB TBXU Direxion Daily Biotech Top 5 Bull 2X ETF | United States | 6.27% | $2.89M | +33% | Pays out | 43% |
